|
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year Report Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023 10.08.2023 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 10 August 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023. At € 10.9 million or € 0.52 per share, net income was € 3.5 million or 25% lower than in the same period last year. Currency effects in particular reduced the result by around € 2.0 million compared with the previous year. Moreover, increased expenses for future projects in the field of diagnostics and therapy in nuclear medicine had an additional impact. In the Medical segment, sales in the first half of the year amounted to € 52.6 million, around € 11.1 million or 27% above the previous year’s level. Main growth driver continued to be the business with pharmaceutical radioisotopes, with sales of laboratory equipment also continuing to increase. The Isotope Products segment generated sales of € 65.3 million, € 0.6 million lower than in the first six months of 2022. Almost all main product groups remained stable, however, high-margin sales of radiation sources for applications in the energy sector recorded a weaker first half than in the previous year. The forecast for the financial year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of just under € 230 million and net income of around € 25 million. The complete quarterly report can be viewed here: About Eckert & Ziegler. Your contact: 10.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy
LONDON — The Japanese firm Kyowa Kirin is acquiring gene therapy maker Orchard Therapeutics in a $400 million deal, the companies said Thursday. Kyowa Kirin
October 5, 2023